Monoclonal antibody therapy

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

Retrieved on: 
Monday, September 6, 2021
Clinical medicine, Medicine, Cancer treatments, Antineoplastic drugs, Immunology, Biotechnology, Antibody-drug conjugate, Immune checkpoint, Monoclonal antibody therapy, Biopharmaceutical, Chemotherapy, Immune system

(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.

Key Points: 
  • (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
  • In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
  • Linker stability is extremely important in the field of antibody immune agonist conjugates.
  • GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.

Rybrevant Amivantamab FDA Approval To Drive Bispecific Antibody Sales To US 20 Billion by 2026

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Clinical medicine, Immunology, Medicine, Monoclonal antibody, Antibody, Bispecific monoclonal antibody, Epidermal growth factor receptor, MorphoSys, Monoclonal antibody therapy

https://www.kuickresearch.com/report-global-usa-europe-japan-bispecific-...

Key Points: 
  • Recently, the progress in antibody and recombinant DNA technology, various platforms for generating bispecific antibodies has been developed.
  • In May, 2021 US FDA has granted approval to Rybrevant (Amivantamab) which is a novel bispecific antibody developed by Janssen Pharmaceuticals.
  • Rybrevant is a fully human bispecific antibody which is directed against EGFR and MET receptors.
  • Among region, US is currently dominating the global bispecific antibody market and is expected to lead the market during the forecast period.

Global and China Bispecific Antibody Market Insight Report, 2021-2024: Roche, Johnson & Johnson and Amgen have Accelerated the Deployment of Bispecific Antibody Products - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Immunology, Clinical medicine, Health care, Amgen, Bispecific monoclonal antibody, Antibody, Trifunctional antibody, Monoclonal antibody therapy

The "Global and China Bispecific Antibody Market Insight Report, 2021-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global and China Bispecific Antibody Market Insight Report, 2021-2024" report has been added to ResearchAndMarkets.com's offering.
  • The first batch of antibody drug patents expired, and tumor necrosis factor TNF, Her2 and CD20 target drugs gradually declined.
  • Global antibody giants Roche, Johnson & Johnson and Amgen have accelerated the deployment of bispecific antibody products.
  • Among the 10 antibody drugs in clinical practice of Johnson & Johnson Company, 8 are bispecific antibodies and 1 is in phase III clinical practice.

Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, June 28, 2021
Medical specialties, Immunology, Clinical medicine, Medicine, Monoclonal antibody therapy, Monoclonal antibody, Antibody, Humanized antibody

In the 35 years since the first approval, monoclonal antibody therapies have become mainstream and their production is considered a routine, platform process.

Key Points: 
  • In the 35 years since the first approval, monoclonal antibody therapies have become mainstream and their production is considered a routine, platform process.
  • However, a high proportion of candidate therapeutic antibody drugs fail to come through early development and Chemistry, Manufacturing and Control (CMC) without challenges.
  • This webinar will focus on how to address these challenges, highlighting examples of where they have been overcome to de-risk early-stage CMC and delivery of clinical trials material.
  • For more information, or to register for this event, visit Early Therapeutic Antibody Development: Addressing the Challenges to Expedite a CMC Program.

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

Retrieved on: 
Tuesday, June 8, 2021
Compugen, Medical specialties, Immunology, Anat Cohen-Dayag, Health care, Immune system, Medicine, Immune checkpoint, Monoclonal antibody therapy

COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen.

Key Points: 
  • COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen.
  • "These new data from our COM701 clinical program are meaningful for two key reasons," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.
  • Dr. Cohen-Dayag continued, "Second, preliminary biomarker data provide important insights into the mechanism of COM701 immune activation.
  • The presentation presented at the ASCO 2021 Annual Meeting can be found at the Company's website and is not considered a part of this press release.

Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Immunology, Antibody, Monoclonal antibody therapy, Branches of biology, Biology, Life sciences

(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m.

Key Points: 
  • (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m.
  • The live webcast of the presentation will be available on the Investors page of the Company's website .
  • An archived presentation will be available on the Merus website for a limited time.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics .

IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer

Retrieved on: 
Tuesday, May 25, 2021
Companies, Medical specialties, Pharmaceutical companies, AstraZeneca, Medical research, Södertälje Municipality, Monoclonal antibody therapy, PD-L1, Io, MedImmune, Compugen

"We are thrilled that Dr. Al-Hajj is joining IO Biotech at such an exciting time in the development of our company," saidMai-Britt Zocca, PhD, Chief Executive Officer, and founder of IO Biotech.

Key Points: 
  • "We are thrilled that Dr. Al-Hajj is joining IO Biotech at such an exciting time in the development of our company," saidMai-Britt Zocca, PhD, Chief Executive Officer, and founder of IO Biotech.
  • "He is a well-respected scientific leader with deep expertise and a proven track record in the field of immuno-oncology with expertise in translational medicine and biomarker discovery.
  • Muhammad was also a group leader in Oncology R&D at MedImmune (AstraZeneca) where he led programs and a team developing antibody therapeutics.
  • IO Biotech is advancing its lead immuno-oncology candidates, IO102 and IO103 targeting IDO and PD-L1, respectively, in clinical studies and several pipeline candidates through preclinical development.

Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors

Retrieved on: 
Wednesday, May 19, 2021
Immunology, XC2, Monoclonal antibody therapy, Antibody, Branches of biology, Biology, Life sciences

TNB-409\xe2\x80\x99s extended half-life and demonstrable safety in monkeys potentially confers a better therapeutic window for the treatment of solid tumors.

Key Points: 
  • TNB-409\xe2\x80\x99s extended half-life and demonstrable safety in monkeys potentially confers a better therapeutic window for the treatment of solid tumors.
  • TNB-409 is poised to enter phase 1 clinical studies in Q2 of 2022.\nKatherine Harris, VP of Discovery at Teneobio added, \xe2\x80\x9cTNB-409 couples the beneficial aspects of IL-2 with Fc-mediated extended half-life, while avoiding the undesirable side effects associated with binding to IL-2R\xce\xb1.
  • TNB-409 not only achieves the desired biological activity of stimulating T and NK effector cells, moreover, it validates the applicability of Teneobio\xe2\x80\x99s human single domain platform of multispecifics to target other therapeutically relevant receptor signaling pathways.
  • Versatile antibody variable domains (UniDab\xc2\xae) derived from\xc2\xa0UniAb\xc2\xae can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics.\xc2\xa0Teneobio\xe2\x80\x99s \xe2\x80\x9cplug-and-play\xe2\x80\x9d T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.\n'

Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 11, 2021
Immunology, XC2, Antibody, Monoclonal antibody therapy, Branches of biology, Biology

b"UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V .

Key Points: 
  • b"UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V .
  • (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics\xc2\xae and Triclonics\xc2\xae), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET.\nThe live webcast of the presentation will be available on the Investors page of the Company's website .
  • An archived presentation will be available on the Merus website for a limited time.\nMerus is a clinical-stage oncology company developing innovative full-length human bispecific and\xc2\xa0trispecific antibody therapeutics, referred to as Multiclonics\xc2\xae .
  • For additional information, please visit Merus\xe2\x80\x99 website and twitter .\n"

CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Immunology, Monoclonal antibody therapy, Cancer, Medicine, Health care

We are developing a novel class of investigational conditionally activated antibody therapeutics, based on our Probody\xc2\xae technology platform, for the treatment of cancer.

Key Points: 
  • We are developing a novel class of investigational conditionally activated antibody therapeutics, based on our Probody\xc2\xae technology platform, for the treatment of cancer.
  • As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies.
  • The CytomX clinical-stage pipeline comprises five assets, four of which are in Phase 2 clinical studies.
  • For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter .\nThis press release includes forward-looking statements.